2021 global life sciences outlook
Possibility is now reality, sustaining forward momentum
Navigating the pandemic has been an all-encompassing, once-in-a-lifetime challenge. Globally, life sciences companies responded with leadership and are emerging stronger. Explore how life sciences companies responded and areas where they can build resiliency going forward.
Intelligent drug launch and commercial
Optimising value through AI
A report on how AI can improve biopharma launches and sales, helping to get the right drugs to the right patients and gain a competitive edge.
Realising a biotech’s potential
What is required to scale successfully?
As biotech companies attract fresh investment, they need to consider how they can scale-up in order to deliver on their promise of providing innovative medicines.
Securing trust in the global COVID-19 supply chain
From development and delivery to acceptance and administration
COVID-19 vaccines and therapeutics, and the associated medical devices and consumables, present an urgent need for a protected supply chain and a system of traceability built around globally identified products.
Breaking barriers to digitalization in biopharma
The pandemic's impact on R&D and commercial operating models
The COVID-19 pandemic has changed the way biopharma does business, from trials to manufacture to sales. Once things get back to normal, will it be business as usual or will the industry evolve and implement learnings from this period?
Bringing new therapies to patients
Transforming clinical development
Transformative approaches to drug development have the potential to improve the efficiency of R&D, bring new therapies to market earlier, and improve the patient experience during clinical trials. What can biopharma companies do to expand their application?
Scaling up AI across the life sciences value chain
Enhancing R&D, creating efficiencies, and increasing impact
AI is already helping improve process efficiency in the life sciences industry. The next three to five years are likely to prove AI’s value in R&D, especially in drug discovery, and across other areas of the value chain.
Benchmarking product development in medtech
What high-performing companies are doing differently
Specific benchmarks—particularly in predictability and revenue contribution—can provide meaningful insights into I&PD performance for medtech organizations. Discover what companies are doing to drive greater market share and higher return on R&D investment.
AI in Biopharma
Forging the links across the value chain
Explore Deloitte's collection of content surrounding biopharma industry trends with a focus on AI in biopharma.
Improved clinical efficiency and quality
How can medtech meet physicians' digital technology needs?
With physicians expecting the use of digital technologies in care delivery to grow in the next five years, medtech manufacturers have an untapped opportunity to team with them in driving clinical efficiency and care quality.
RWE focus is shifting to R&D, early investments begin to payoff
How can others catch up?
Companies that have invested in mature RWE capabilities are seeing returns; others are behind. Results from Deloitte’s third RWE benchmarking study reveal how companies still building their capabilities can catch up.
New payment models in medtech
Regulatory, technology, and marketplace trends converging to create new opportunities for manufacturers
Medtech manufacturers are rising to the challenge to deliver value through new payment models. To be successful, they will likely need to identify the right customers, construct the right contract, implement a new go-to-market model, and navigate regulatory constraints.
Striving to become more patient-centric in life sciences
What it really takes to optimize patient trust and health outcomes
In a world where the consumer is increasingly becoming more empowered, life sciences companies should challenge the status quo and embrace opportunities to adopt a wide range of patient-centered approaches presented by an emerging ecosystem.
Picking up speed to become a reality for the future of health
The future of health envisions timely and relevant exchange of health and other data between consumers, physicians, health care and life sciences organizations, and new entrants. What will it take for the industry to get there?
Winning in the future of medtech
Novel partnerships with consumer tech to transform care delivery
Medtech companies are well-positioned to drive the future of health, but most cannot do it alone. They should instead partner with consumer technology and specialized digital health companies to meet the changing market.
Digital transformation in life sciences
How pharma and medtech can shift from doing digital to being digital
Digital transformation is no longer a buzzword—it’s a strategic imperative. How can life sciences companies advance their capabilities and take a more holistic view of their digital strategies?
Neurowissenschaften können Pharma-Unternehmen bei der Markteinführung von neuen Medikamenten unterstützen
Ein Point of View des Deloitte Neuroscience Institute
In unserer Studie des Deloitte Neuroscience Institute "Using neurosciences for product launches" erfahren Sie, wie Neurowissenschaften Pharma-Unternehmen bei der Markteinführung von neuen Medikamenten unterstützen können.
eHealth und das Spiel mit den Daten
Wie Connected Care die MedTech Industrie verändert
In einer Welt, in der eHealth das Gesundheitssystem regiert und neue Wettbewerber den Markt erobern, sind MedTech Unternehmen gefordert, ihre Rolle neu definieren.
Patient access to innovative medicine in Europe
A collaborative and value-based approach
The new research explores the current market access and pricing challenges presented by the European market, and provides recommendations on how pharma companies can work more collaboratively with payers to help patients gain access to the latest medical innovations.
Life Sciences and Health Care Industry Readout Global CIO Survey 2018
AI and machine learning are top priorities for CIOs in the Life Sciences and Health Care Industry
The Life Sciences and Health Care Industry Readout of the Global CIO Survey 2018 shows that this sector leads the pack in its number of CIOs that are currently already business co-creators.
Survey finds biopharma companies lag in digital transformation
It is time for a sea change in strategy
The life sciences industry's commitment to digital transformation is increasing, but few organizations are digitally maturing. Here's how companies can take an enterprisewide approach to digital transformation.